Should I buy or sell Talaris Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Talaris Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TALS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TALS, but not buy additional shares or sell existing shares. View TALS analyst ratings or view top-rated stocks .

What is Talaris Therapeutics' stock price target for 2024?

2 brokerages have issued 12-month price objectives for Talaris Therapeutics' shares. Their TALS share price targets range from $3.00 to $12.00. On average, they predict the company's share price to reach $7.50 in the next twelve months. This suggests that the stock has a possible downside of 60.5%. View analysts price targets for TALS or view top-rated stocks among Wall Street analysts .

How have TALS shares performed in 2023?

Talaris Therapeutics' stock was trading at $1.02 at the beginning of 2023. Since then, TALS stock has increased by 1,759.8% and is now trading at $18.97. View the best growth stocks for 2023 here .

How were Talaris Therapeutics' earnings last quarter?

Talaris Therapeutics, Inc. (NASDAQ:TALS) posted its quarterly earnings data on Friday, November, 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.03.

How often does Talaris Therapeutics pay dividends? What is the dividend yield for Talaris Therapeutics?

Talaris Therapeutics announced a dividend on Thursday, October 19th. Stockholders of record on Monday, October 16th will be paid a dividend of $1.5118 per share on Friday, October 20th. The ex-dividend date of this dividend is Friday, October 20th. Read our dividend analysis for TALS .

When did Talaris Therapeutics IPO?

(TALS) raised $150 million in an initial public offering on Friday, May 7th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities served as the underwriters for the IPO.

Who are Talaris Therapeutics' major shareholders?

Talaris Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include RA Capital Management L.P. (5.62%), Affinity Asset Advisors LLC (0.94%), Walleye Capital LLC (0.61%), Acuitas Investments LLC (0.45%), Marquette Asset Management LLC (0.09%) and Barclays PLC (0.04%). Insiders that own company stock include Francois Nader, Longitude Capital Partners Iii, Sandip Agarwala, Scott Requadt and Suzanne Ildstad. View institutional ownership trends .

How do I buy shares of Talaris Therapeutics?

Shares of TALS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Talaris Therapeutics Stock Price, News & Analysis (NASDAQ:TALS)

$18.97

-0.03 (-0.16%)

(As of 12/5/2023 ET)

Compare

Today's Range: $18.59
▼
$19.26
50-Day Range: $2.59
▼
$19.50
52-Week Range: $0.89
▼
$27.95

Volume: 76,969 shs
Average Volume: 386,531 shs
Market Capitalization: $811.23 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.50

About Talaris Therapeutics Stock (NASDAQ:TALS)

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.

TALS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TALS Stock News Headlines

November 1, 2023 | msn.com

Talaris Therapeutics (TALS) Price Target Increased by 562.50% to 135.15

October 19, 2023 | msn.com

Talaris Therapeutics goes ex-dividend tomorrow

December 6, 2023 | Edge On The Street (Ad)

Americans Now Favor Gold Over Stocks as an Investment Vehicle

Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.

October 18, 2023 | finanznachrichten.de

Talaris Therapeutics, Inc.: Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio

October 17, 2023 | msn.com

Talaris shareholders approve merger, 1-for-10 reverse stock split

October 17, 2023 | finance.yahoo.com

Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio

October 6, 2023 | marketwatch.com

Shares of Talaris Therapeutics Climb 5.2% on Special Dividend Tied to Merger

October 6, 2023 | finance.yahoo.com

Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio

December 6, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

October 4, 2023 | finance.yahoo.com

New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics

September 12, 2023 | finance.yahoo.com

We're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate

August 15, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, DEN, TALS, QUOT

August 14, 2023 | finance.yahoo.com

ImmunoFree Inc. has Acquired Talaris Therapeutics, Inc.'s Tolerance Business

August 8, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, TALS, QUOT, SURF

July 28, 2023 | benzinga.com

Moore Kuehn Encourages RETA, TALS, INPX, and DEN Investors to Contact Law Firm

July 27, 2023 | markets.businessinsider.com

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Talaris Therapeutics, Inc. (TALS)

July 18, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NETI, QUOT, TALS, CFMS

July 18, 2023 | msn.com

Talaris Therapeutics: Cashing Out Ahead Of Tourmaline Merger

July 6, 2023 | msn.com

Talaris Therapeutics (TALS) Price Target Increased by 66.67% to 12.75

June 27, 2023 | markets.businessinsider.com

IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, DICE, NEX, NETI

June 26, 2023 | businesswire.com

TALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALS

June 23, 2023 | benzinga.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Talaris Therapeutics, Inc. Merger

June 23, 2023 | bizjournals.com

Talaris Therapeutics announces merger after layoffs

June 22, 2023 | bizjournals.com

NY biotech to go public by merging with Boston firm that laid off 95% of staff

June 22, 2023 | msn.com

Talaris jumps 29% on merger with Tourmaline Bio in all-stock deal

June 22, 2023 | markets.businessinsider.com

IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, SURF, NEX, CIR

June 22, 2023 | finanznachrichten.de

Talaris Therapeutics, Inc.: Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement

See More Headlines

Receive TALS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Talaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/12/2021
Ex-Dividend for 10/20 Dividend: 10/20/2023
Dividend Payable: 10/20/2023
Today: 12/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TALS
CUSIP: N/A
CIK: 1827506
Web: talaristx.com
Phone: 502-398-9250
Fax: N/A
Employees: 84
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.50
High Stock Price Target: $12.00
Low Stock Price Target: $3.00
Potential Upside/Downside: -60.5%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.79)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-73,890,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -39.93%
Return on Assets: -37.37%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 15.41
Quick Ratio: 15.41

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.33 per share
Price / Book: 4.38

Miscellaneous

Outstanding Shares: 42,764,000
Free Float: 35,708,000
Market Cap: $811.23 million
Optionable: Not Optionable
Beta: 2.18

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Ms. Mary Kay Fenton (Age 59)
Interim CEO, Pres, CFO & Treasurer
Comp: $598.98k
Dr. Suzanne T. Ildstad M.D. (Age 70)
Founder, Member of Scientific Advisory Board, Sr. Scientific Advisor & Director
Comp: $318.3k
Ms. Suzanne Tollerud
VP of Corp. Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TALS Stock Analysis - Frequently Asked Questions

Should I buy or sell Talaris Therapeutics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Talaris Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TALS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TALS, but not buy additional shares or sell existing shares.
View TALS analyst ratings or view top-rated stocks.
What is Talaris Therapeutics' stock price target for 2024?: 2 brokerages have issued 12-month price objectives for Talaris Therapeutics' shares. Their TALS share price targets range from $3.00 to $12.00. On average, they predict the company's share price to reach $7.50 in the next twelve months. This suggests that the stock has a possible downside of 60.5%.
View analysts price targets for TALS or view top-rated stocks among Wall Street analysts.
How have TALS shares performed in 2023?: Talaris Therapeutics' stock was trading at $1.02 at the beginning of 2023. Since then, TALS stock has increased by 1,759.8% and is now trading at $18.97.
View the best growth stocks for 2023 here.
How were Talaris Therapeutics' earnings last quarter?: Talaris Therapeutics, Inc. (NASDAQ:TALS) posted its quarterly earnings data on Friday, November, 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.03.

How often does Talaris Therapeutics pay dividends? What is the dividend yield for Talaris Therapeutics?: Talaris Therapeutics announced a dividend on Thursday, October 19th. Stockholders of record on Monday, October 16th will be paid a dividend of $1.5118 per share on Friday, October 20th. The ex-dividend date of this dividend is Friday, October 20th.
Read our dividend analysis for TALS.
When did Talaris Therapeutics IPO?: (TALS) raised $150 million in an initial public offering on Friday, May 7th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities served as the underwriters for the IPO.
Who are Talaris Therapeutics' major shareholders?: Talaris Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include RA Capital Management L.P. (5.62%), Affinity Asset Advisors LLC (0.94%), Walleye Capital LLC (0.61%), Acuitas Investments LLC (0.45%), Marquette Asset Management LLC (0.09%) and Barclays PLC (0.04%). Insiders that own company stock include Francois Nader, Longitude Capital Partners Iii, Sandip Agarwala, Scott Requadt and Suzanne Ildstad.
View institutional ownership trends.
How do I buy shares of Talaris Therapeutics?: Shares of TALS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TALS) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial